Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

5articles mentioning drugs

14drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: DLCO ×

DLCO

This drug is selected. Its supporting articles are shown below.

Articles mentioning DLCO

5 articles · page 1 of 1

P71 Inter- and intra-session variability of the VitaloROV+ and VitaloLAB pulmonary function testing equipment in healthy volunteers

bmjresp · abstract · 2025-09-16 · 6 matching annotations

92.1%

DLco carbon monoxide

…formance standards. Results of simulation testing verified that DLco measurements obtained using the VitaloROV+ and VitaloLAB system…

Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension

thoraxjnl · abstract · 2026-01-07 · 3 matching annotations

95.1%

DLco carbon monoxide chronic thromboembolic pulmonary hypertension microvasculopathy balloon pulmonary angioplasty Japanese nationwide registry

… 0.971, p=0.005). Outcomes deteriorated below 59.6%, indicating DLco may help stratify prognosis and treatment benefit.…

P.116 Analysis and validation of the different progressive pulmonary fibrosis (PPF) criteria in a cohort of patients with interstitial lung disease associated to systemic sclerosis (SSc-ILD

jsrd · abstract · 2026-06-05 · 2 matching annotations

82.8%

DLCO Hospital Universitari Vall d’Hebron systemic sclerosis (SSc-ILD)Interstitial lung disease (ILD)SSc-ILD

…% or FVC 5-9%), 3) ATS 2022 (absolute decline FVC ≥ 5% or DLCO ≥ 10%) and 4) an absolute decline of absolute FVC ≥…

P.133 Change in DLCO over time as a predictor of mortality in SSc-PAH

jsrd · abstract · 2026-06-05 · 2 matching annotations

80.4%

DLCO Oslo University Hospital systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH)SSc-PAH OUH OUH-SSc

…sensitive to change after PAH-diagnosis. Patients without early DLCO% decline showed a trend towards improved survival. DLCO% may th…

Gender differences in clinical features, comorbidities and prognostic outcomes in idiopathic pulmonary fibrosis—a retrospective cohort analysis from the British Thoracic Society Interstitial Lung Disease Registry

bmjopen · abstract · 2025-10-28 · 1 matching annotations

80.5%

DLCO Hiatus hernia gastro-oesophageal reflux disease Idiopathic pulmonary fibrosis (IPF)ischaemic heart disease (IHD)diabetes interstitial lung disease (ILD)

…emales (p=0.001), while diffusing capacity for carbon monoxide (DLCO) was similar between the two groups. In multivariate analysis, …